Gland Pharma Ltd.

NSE: GLAND BSE: 543245 SECTOR: Pharmaceuticals & Drugs  66k   572   83

1310.55
-45.95 (-3.39%)
NSE: Today, 03:57 PM

Price Summary

Today's High

₹ 1360.5

Today's Low

₹ 1307.45

52 Week High

₹ 3598

52 Week Low

₹ 1308.35

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

21583.48 Cr.

Enterprise Value

18501.61 Cr.

No. of Shares

16.47 Cr.

P/E

21.97

P/B

2.74

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  478.31

CASH

3085.8 Cr.

DEBT

3.93 Cr.

Promoter Holding

57.86 %

EPS (TTM)

₹  59.66

Sales Growth

27.08%

ROE

18.62 %

ROCE

24.86%

Profit Growth

21.58 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 23 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year27.08%
3 Year29.12%
5 Year24.37%

Profit Growth

1 Year21.58%
3 Year38.94%
5 Year23.98%

ROE%

1 Year18.62%
3 Year21.13%
5 Year18.96%

ROCE %

1 Year24.86%
3 Year27.85%
5 Year26.41%

Debt/Equity

0.0006

Price to Cash Flow

27.28

Interest Cover Ratio

309.977671755725

CFO/PAT (5 Yr. Avg.)

0.66154998656472

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 57.86 0
Sep 2022 57.86 0
Jun 2022 57.87 0
Mar 2022 58 0
Dec 2021 58 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 38.9429011883194% for the Past 3 years.
  • The company has shown a good revenue growth of 29.1214518083462% for the Past 3 years.
  • Company has been maintaining healthy ROE of 21.1328771168802% over the past 3 years.
  • Company has been maintaining healthy ROCE of 27.8464718538104% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 309.977671755725.
  • The Company has been maintaining an effective average operating margins of 35.1485560845307% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 10.0430819831013.
  • The company has a high promoter holding of 57.86%.

 Limitations

  • The company is trading at a high PE of 21.97.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 1063.33 1103.01 856.9 1048.31 925.9
Total Expenditure 714.06 754.58 586.7 753.07 641.94
Operating Profit 349.27 348.43 270.2 295.24 283.96
Other Income 45.67 65.23 74.39 65.62 61.51
Interest 1.18 2.03 0.9 1.72 2.62
Depreciation 27.83 31.08 34.91 36.67 37.61
Exceptional Items 0 0 0 0 0
Profit Before Tax 365.92 380.56 308.78 322.47 305.24
Tax 92.53 94.58 79.33 82.84 77.7
Profit After Tax 273.38 285.98 229.45 239.63 227.54
Adjusted EPS (Rs) 16.64 17.41 13.94 14.55 13.82

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 1619.94 2044.2 2633.24 3462.88 4400.71
Total Expenditure 1084.84 1337.89 1677.77 2160.61 2890.07
Operating Profit 535.11 706.31 955.47 1302.27 1510.64
Other Income 48.79 85.56 139.17 134.78 223.94
Interest 4.13 3.56 7.18 3.41 5.24
Depreciation 78.21 81.96 94.59 98.78 110.3
Exceptional Items 0 -20 0 0 0
Profit Before Tax 501.56 686.36 992.87 1334.85 1619.04
Tax 180.45 234.45 220.01 337.85 406.89
Net Profit 321.11 451.91 772.86 997.01 1212.16
Adjusted EPS (Rs.) 207.24 291.65 49.88 60.95 73.78

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 15.5 15.5 15.5 16.36 16.43
Total Reserves 2394.93 2846.62 3630.74 5886.93 7141.8
Borrowings 5.49 4.96 4.07 3.93 3.82
Other N/C liabilities 133.88 122.83 76.71 76.38 90.15
Current liabilities 378.55 532.68 359.02 512.46 581.94
Total Liabilities 2928.34 3522.58 4086.04 6496.06 7834.14
Assets
Net Block 842.64 928.74 968.1 954.23 1502.19
Capital WIP 198.88 123.16 188.47 337.81 180.75
Intangible WIP 0 0 0 0 10
Investments 0 0 0 0.55 8.16
Loans & Advances 33.89 111.89 81.52 77.97 286.4
Other N/C Assets 1.95 1.33 1.66 2.43 2.21
Current Assets 1850.98 2357.46 2846.29 5123.07 5844.44
Total Assets 2928.34 3522.58 4086.04 6496.06 7834.14
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 501.56 686.36 992.87 1334.85 1619.04
Adjustment 50.94 76.12 32.15 17.3 -28.19
Changes in Assets & Liabilities -193.43 -353.95 -79.94 -435.8 -393.05
Tax Paid -157.14 -223.47 -244.14 -311.43 -406.51
Operating Cash Flow 201.93 185.06 700.94 604.93 791.29
Investing Cash Flow -358.57 -318.57 -760.97 -1520.97 -1006.92
Financing Cash Flow -3.59 -2.93 -6.87 1238.46 34.9
Net Cash Flow -160.24 -136.44 -66.9 322.42 -180.73

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 58.00 58.00 57.87 57.86 57.86
fosun pharma indus... 58.00 58.00 57.87 57.86 57.86
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 42.00 42.00 42.13 42.14 42.14
gland celsus bio c... 6.12 - - - -
nicomac machinery ... - 5.81 1.93 1.19 1.19
axis mutual fund t... 3.91 4.19 4.24 4.12 2.65
mirae asset large ... - - 2.82 3.86 3.98
icici prudential i... - - - - 3.88
government of sing... 1.11 - 1.05 - -
r p advisory servi... 2.61 2.61 2.61 2.61 2.61
nippon life india ... - - - 1.60 2.26
icici prudential b... - - - 1.37 -
new world fund inc 1.27 1.27 - - -
uti flexi cap fund - - - - 1.24
smallcap world fun... 1.20 - - - -
motilal oswal flex... 1.06 - - - -
r p advisory servi... 1.14 1.14 1.14 1.14 1.14
aditya birla sun l... - - 1.09 - 1.10
canara robeco mutu... - - 1.06 - -
kotak emerging equ... - - - - 1.05
llp 0.12 0.10 0.11 - 0.09

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Company News

USFDA conducts inspection at Gland Pharma’s API Facility in Visakhapatnam27 Jan 2023, 4:03PM Gland Pharma informs about analyst meet27 Jan 2023, 3:01PM Gland Pharma reports 15% fall in Q3 consolidated net profit24 Jan 2023, 12:17PM Gland Pharma - Quaterly Results23 Jan 2023, 4:12PM Gland Pharma - Quaterly Results23 Jan 2023, 4:12PM Gland Pharma - Quaterly Results23 Jan 2023, 4:12PM Gland Pharma’s arm inks share purchase agreement with FPCI Sino French Midcap Fund 7 Jan 2023, 3:11PM Gland Pharma receives EIR from US FDA for Dundigal Facility at Hyderabad4 Jan 2023, 12:21PM Gland Pharma informs about trading window closure30 Dec 2022, 4:27PM Gland Pharma informs about investors meeting26 Dec 2022, 12:29PM Gland Pharma informs about analyst meet intimation12 Dec 2022, 5:06PM Gland Pharma informs about analyst meet5 Dec 2022, 12:20PM Gland Pharma enters into put option agreement to acquire 100% stake in Cenexi Group30 Nov 2022, 10:29AM Gland Pharma informs about analyst meet intimation24 Nov 2022, 4:57PM Gland Pharma informs about investors meet28 Oct 2022, 9:27AM Gland Pharma reports 20% fall in Q2 consolidated net profit27 Oct 2022, 2:08PM Gland Pharma informs about earnings call recording27 Oct 2022, 11:44AM Gland Pharma - Quaterly Results26 Oct 2022, 3:42PM Gland Pharma - Quaterly Results26 Oct 2022, 3:42PM Gland Pharma informs about analyst meet20 Sep 2022, 3:47PM Gland Pharma informs about analyst meet12 Sep 2022, 4:18PM Gland Pharma informs about analyst meet9 Sep 2022, 4:38PM Gland Pharma informs about analyst meet6 Sep 2022, 12:47PM Gland Pharma informs about analyst meet26 Aug 2022, 4:43PM Gland Pharma informs about earrings call21 Jul 2022, 9:39AM Gland Pharma informs about investor presentation20 Jul 2022, 5:03PM Gland Pharma - Quaterly Results20 Jul 2022, 3:59PM Gland Pharma - Quaterly Results20 Jul 2022, 3:59PM Gland Pharma - Quaterly Results20 Jul 2022, 3:59PM Gland Pharma informs about analyst meet13 Jun 2022, 4:42PM Gland Pharma informs about analyst meet6 Jun 2022, 4:40PM Gland Pharma informs about analyst meet20 May 2022, 12:10PM Gland Pharma informs about earnings call recording20 May 2022, 12:03PM Gland Pharma - Quaterly Results19 May 2022, 4:08PM Gland Pharma - Quaterly Results19 May 2022, 4:08PM Gland Pharma - Quaterly Results19 May 2022, 4:08PM Gland Pharma launches Bortezomib for injection in US market4 May 2022, 3:06PM Gland Pharma informs about disclosure23 Apr 2022, 10:31AM Gland Pharma informs about analyst meet22 Mar 2022, 4:38PM Gland Pharma informs about analyst meet9 Mar 2022, 3:17PM Gland Pharma informs about analyst meet8 Mar 2022, 12:54PM Gland Pharma informs about analyst meet7 Mar 2022, 5:37PM Gland Pharma informs about analyst meet24 Jan 2022, 2:46PM Gland Pharma informs about newspaper advertisement22 Jan 2022, 3:11PM Gland Pharma informs about monitoring agency report 22 Jan 2022, 10:29AM Gland Pharma - Quaterly Results21 Jan 2022, 3:40PM Gland Pharma informs about disclosure6 Jan 2022, 9:39AM Gland Pharma informs about disclosure6 Jan 2022, 9:37AM Gland Pharma informs about analyst meet15 Dec 2021, 3:39PM Gland Pharma receives USFDA’s tentative approval for Cangrelor for Injection8 Dec 2021, 4:58PM

Gland Pharma Stock Price Analysis and Quick Research Report. Is Gland Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Gland Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 791.287 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Gland Pharma has a Debt to Equity ratio of 0.0006 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Gland Pharma , the EPS growth was 21.0540910388643 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Gland Pharma has OPM of 34.327180989968 % which is a good sign for profitability.
     
  • ROE: Gland Pharma have a average ROE of 18.6158147232265 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Gland Pharma

X